Alex Goldberg

NASDAQ Active Stock Watch List: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Celldex Therapeutics, Inc. (NASDAQ:CLDX) Added to Equity Profile Report's NASDAQ Active Stock Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 02/18/2014 -- Equity Profile Report expands its NASDAQ Active Stock Weekly Watch List adding BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Celldex Therapeutics, Inc. (NASDAQ:CLDX).

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) a company that develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally is currently down (-1.73%) on 753,225 shares traded after BIOMARIN PHARMACEUTICAL INC Filed SEC form 8-K, Regulation FD Disclosure. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is currently down (-8.65%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.

Click Here to find out what other Investors are saying about BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Celldex Therapeutics, Inc. (NASDAQ:CLDX) a biopharmaceutical company that focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States is currently up (+1.76%) on 757,970 shares traded. Celldex Therapeutics, Inc. (NASDAQ:CLDX) is currently up (+235.02%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.

Click Here to find out what other Investors are saying about Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com